GLP-1 Medication Cost Guide: How to Save on Wegovy, Ozempic, and Zepbound in 2026

TLDR

GLP-1 medications — Wegovy, Ozempic, Zepbound, and Mounjaro — carry list prices between $935 and $1,349 per month without insurance. But most commercially insured patients pay far less through manufacturer savings cards that can bring the cost down to as little as $25 per month or even $0. Medicare and Medicaid patients are excluded from these savings programs, and weight management GLP-1s (Wegovy, Zepbound) are not covered by traditional Medicare Part D. This guide breaks down the real costs, every savings option available, and how telehealth platforms like Klarity can make GLP-1 access more affordable and straightforward.

Table of Contents

• How Much Each GLP-1 Costs Without Insurance
• Manufacturer Savings Cards and Coupons
• How Insurance Coverage Works
• Medicare and Medicaid Coverage Gaps
• Patient Assistance Programs
• Telehealth as a Cost-Saving Option
• How Klarity Makes GLP-1 Access More Affordable

How Much Each GLP-1 Costs Without Insurance

The sticker price of GLP-1 medications is genuinely high. Here is what each medication costs at list price before any savings programs, insurance, or discounts apply:

These are list prices — the number on the pharmacy receipt before any negotiation, insurance, or coupon is applied. Almost no commercially insured patient pays full list price.

A few key distinctions worth understanding:

• Semaglutide vs. tirzepatide: Ozempic and Wegovy both contain semaglutide (a GLP-1 receptor agonist). Mounjaro and Zepbound both contain tirzepatide, which activates both GLP-1 and GIP receptors — a dual mechanism associated with greater average weight loss in clinical trials.
• Diabetes vs. weight management: Ozempic and Mounjaro are FDA-approved for Type 2 diabetes. Wegovy and Zepbound are FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The indication affects insurance coverage significantly (more on that below).
• Dose escalation: All four medications are titrated up over several months. The list prices above reflect maintenance doses — your first few months at starter doses may cost slightly less.

Manufacturer Savings Cards and Coupons

Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically cut your out-of-pocket cost — if you qualify. Eligibility hinges on your insurance status.

Wegovy Savings Card (Novo Nordisk)

Program: NovoCare Wegovy Savings Offer Program

• Commercially insured patients who qualify may pay as little as $0 or $25 per month
• Available for adults and for caregivers of adolescents ages 12 to 17
• To enroll: text SAVE to 83757 or visit novocare.com/wegovy
• Not available for patients on Medicare, Medicaid, or any other government-funded healthcare program

Ozempic Savings Card (Novo Nordisk)

Program: NovoCare Ozempic Savings Card

• Commercially insured patients may pay as little as $25 per month
• Covers patients with commercial (private) insurance using Ozempic for its FDA-approved indication (Type 2 diabetes)
• Enroll at novocare.com/ozempic
• Not available for Medicare or Medicaid patients

Zepbound Savings Program (Eli Lilly)

Program: Zepbound Savings Program

• Commercially insured patients (with coverage) may pay starting at $25 for up to a 3-month prescription
• Patients with commercial insurance but no coverage for Zepbound can access the Zepbound KwikPen through a direct program
• Self-pay vial option: Eli Lilly offers Zepbound vials at approximately $550 per month with no insurance required — a meaningful option for patients without coverage who want a brand-name, FDA-approved tirzepatide product
• Enroll at zepbound.lilly.com/savings
• Not available for Medicare, Medicaid, or other government-funded programs

Mounjaro Savings Card (Eli Lilly)

Program: Mounjaro Savings Card

• Commercially insured patients may pay as little as $25 per month
• Applies to patients using Mounjaro for its FDA-approved indication (Type 2 diabetes)
• Enroll at mounjaro.lilly.com/savings-resources
• Not available for Medicare or Medicaid patients

Summary: Who Qualifies for Manufacturer Savings Cards

To use any of these savings programs, you generally must:

1. Have commercial (private) insurance — through an employer, marketplace, or private purchase
2. Have a prescription for the drug's FDA-approved indication (diabetes or weight management, depending on the drug)
3. Be a U.S. resident
4. Not be enrolled in Medicare, Medicaid, CHIP, VA benefits, or any other government-funded healthcare program

If you meet these criteria, manufacturer savings cards are the single most effective way to reduce your GLP-1 cost.

How Insurance Coverage Works

Whether your insurance covers a GLP-1 — and how much it covers — depends on three factors: the drug's indication, your specific plan, and whether you meet clinical criteria.

Diabetes Indication (Ozempic, Mounjaro): Better Coverage

Ozempic and Mounjaro, prescribed for Type 2 diabetes management, are more widely covered by commercial insurance and Medicare Part D. Most major commercial plans include at least one GLP-1 on their formulary for diabetes, though prior authorization (PA) is common.

A typical PA for a diabetes-indication GLP-1 requires:

• A confirmed Type 2 diabetes diagnosis
• Evidence that other first-line medications (like metformin) were tried
• Documentation from your prescribing provider

Weight Management Indication (Wegovy, Zepbound): Patchier Coverage

Coverage for Wegovy and Zepbound for obesity/weight management varies far more by plan. Many commercial insurers exclude weight loss drugs entirely. Others cover them with step therapy requirements (requiring you to first try diet programs or other medications).

To maximize your odds of coverage:

• Ask your provider to document your BMI, related comorbidities (hypertension, sleep apnea, Type 2 diabetes, dyslipidemia), and prior weight loss attempts
• Check your plan's drug formulary for tier placement before filling
• Ask your provider to submit a PA with supporting clinical documentation if required

Medicare and Medicaid Coverage Gaps

This is where the coverage picture is most complicated — and most frustrating for patients.

Traditional Medicare

• Wegovy and Zepbound (weight management): NOT covered by traditional Medicare Part D for obesity treatment alone. Medicare Part D does not include weight loss as a covered indication.
• Ozempic and Mounjaro (Type 2 diabetes): ARE covered by Medicare Part D as diabetes treatments, subject to formulary, tier placement, and out-of-pocket limits.
• Important: Even if you take Ozempic for weight loss off-label, your Medicare plan covers it only if your prescribing diagnosis is diabetes.

Medicare Advantage

Some Medicare Advantage (Part C) plans offer supplemental coverage for weight management drugs. If you are on Medicare Advantage, it is worth calling your plan directly to ask whether Wegovy or Zepbound is covered under your specific plan benefits.

Medicare Prescription Payment Plan (M3P)

For drugs covered under Medicare Part D (like Ozempic or Mounjaro for diabetes), the Medicare Prescription Payment Plan (M3P) is a free budgeting tool that spreads your annual out-of-pocket costs into fixed monthly payments. Enroll at GetMyMeds.com or medicare.gov/prescription-payment-plan.

Medicaid

Medicaid coverage for GLP-1 medications varies by state. Some state Medicaid programs cover GLP-1s for Type 2 diabetes; fewer cover them for weight management. Check your state Medicaid plan's drug formulary, or ask your prescribing provider to check on your behalf.

Savings Cards and Government Insurance

Federal anti-kickback regulations prohibit manufacturers from offering savings cards to Medicare or Medicaid patients. This is not a policy choice by Novo Nordisk or Eli Lilly — it is a federal legal requirement. If you are on Medicare or Medicaid and your GLP-1 is not covered, your options are patient assistance programs (see below), discount pharmacy programs, or telehealth platforms with transparent self-pay pricing.

Patient Assistance Programs

Both Novo Nordisk and Eli Lilly run income-based patient assistance programs for uninsured or underinsured patients who cannot afford their medications.

NovoCare Patient Assistance Program (Novo Nordisk)

Covers Wegovy and Ozempic for patients who:

• Are uninsured or underinsured and do not qualify for the savings card
• Meet income eligibility criteria (generally at or below a percentage of federal poverty guidelines)
• Are U.S. residents

Apply at novocare.com or ask your provider's office to submit on your behalf.

Lilly Cares Foundation Patient Assistance Program (Eli Lilly)

Covers Zepbound and Mounjaro for patients who:

• Are uninsured or meet income criteria
• Are U.S. residents
• Do not have adequate coverage for the requested medication

Apply at lillycares.com or through your provider.

RxAssist and NeedyMeds

Two independent directories — rxassist.org and needymeds.org — aggregate patient assistance programs from all major manufacturers and can help you identify additional programs you may qualify for.

GoodRx and Pharmacy Discount Programs

GoodRx, RxSaver, and similar discount services do not require insurance and can reduce out-of-pocket costs at participating pharmacies. While they will not bring a $1,349/month medication down to $25, they can provide meaningful savings — particularly for lower-dose or short-term prescriptions. Always compare prices across multiple pharmacies, as the same drug can vary by $50 or more depending on location.

Telehealth as a Cost-Saving Option

One underappreciated way to reduce the total cost of GLP-1 treatment is through telehealth platforms that offer transparent, upfront pricing for consultations and prescriptions.

Traditional in-person weight management programs can involve:

• Multiple specialist visits with separate copays
• Lab work billed at facility rates
• Prior authorization delays that can stretch to weeks

Telehealth platforms eliminate most of that friction. You pay a flat consultation fee, receive a prescription if clinically appropriate, and pick up your medication at a pharmacy of your choice — where your savings card or discount program applies just as it would for an in-person prescription.

Telehealth is also a strong option for patients who live in areas with limited access to obesity medicine specialists or endocrinologists, or who have been turned away from traditional providers due to insurance barriers.

How Klarity Makes GLP-1 Access More Affordable

Klarity is a telehealth platform with 2,000+ licensed providers — physicians, nurse practitioners, and physician assistants — available across the United States. Klarity providers evaluate patients for GLP-1 eligibility, write prescriptions for clinically appropriate candidates, and provide ongoing medication management, all online.

Here is how Klarity reduces the cost and friction of GLP-1 access:

• Transparent consultation pricing: No surprise bills or facility fees
• Fast appointments: Most patients book within days, not weeks
• Prescription support: Klarity providers can submit prior authorization documentation and help you navigate your insurance formulary
• Savings card guidance: Providers and care coordinators can walk you through which savings program applies to your insurance situation
• Ongoing follow-up: Medication management, dose adjustments, and follow-up visits — all without leaving home

Whether you have commercial insurance with good GLP-1 coverage, are navigating a coverage denial, or are paying out of pocket, Klarity providers work with your situation to find the most accessible path to treatment.

Ready to explore whether a GLP-1 medication is right for you? Get started with a Klarity provider today — licensed providers available nationwide, with transparent pricing and fast appointments.

Prices listed in this article reflect estimated 2026 list prices and are subject to change. Savings program eligibility and terms may change — always verify current program details directly with the manufacturer. This article is for informational purposes only and does not constitute medical advice.